Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer Journal Article

Authors: Beylergil, V.; Morris, P. G.; Smith-Jones, P. M.; Modi, S.; Solit, D.; Hudis, C. A.; Lu, Y.; O'Donoghue, J.; Lyashchenko, S. K.; Carrasquillo, J. A.; Larson, S. M.; Akhurst, T. J.
Article Title: Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer
Abstract: OBJECTIVE: Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-F(ab')2-trastuzumab [Ga-DOTA-F(ab')2-trastuzumab] has been developed at our institution as a positron imaging reagent for assessing human epidermal growth factor receptor 2 (HER2) expression status by in-vivo imaging. Initial studies on animals demonstrated promising results in the monitoring of treatment response to heat shock protein 90-targeted drugs that inhibit the client protein HER2. We report here our initial clinical experience in the assessment of the toxicity, pharmacokinetics, biodistribution, and dosimetry profile of Ga-DOTA-F(ab')2-trastuzumab with PET/computed tomography using a mean of 236 MBq/5 mg administered intravenously. MATERIALS AND METHODS: A group of 16 women with breast cancer were enrolled in this study. The one patient who did not receive Ga-DOTA-F(ab')2-trastuzumab was excluded from analysis. Both HER2-negative (n=7) and HER2-positive (n=8) cases were studied. Among the latter, seven had undergone trastuzumab treatment previously and one had not. RESULTS: It was determined that Ga-DOTA-F(ab')2-trastuzumab was well tolerated, with a T of ∼3.6±0.9 h; the critical organ was the kidney, with a mean dose of 0.383 cGy/37 MBq; and tumor targeting was seen in 4/8 patients with HER2-positive disease. CONCLUSION: The reagent is safe, and assessments through additional studies in a better-defined group of patients, using larger administered masses of antibodies, with a better immunoreactive fraction are needed. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Keywords: breast cancer; pet/ct; herceptin; 68ga; f(ab0)2-trastuzumab
Journal Title: Nuclear Medicine Communications
Volume: 34
Issue: 12
ISSN: 0143-3636
Publisher: Lippincott Williams & Wilkins  
Date Published: 2013-12-01
Start Page: 1157
End Page: 1165
Language: English
DOI: 10.1097/MNM.0b013e328365d99b
PROVIDER: scopus
PMCID: PMC3815146
PUBMED: 24100444
Notes: --- - "Export Date: 2 December 2013" - "CODEN: NMCOD" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Patrick Glyn Morris
    107 Morris
  2. Clifford Hudis
    840 Hudis
  3. David Solit
    431 Solit
  4. Shanu Modi
    132 Modi
  5. Timothy J Akhurst
    134 Akhurst
  6. Yang Lu
    11 Lu
  7. Steven M Larson
    765 Larson